Literature DB >> 31579207

Diffuse Skeletal Uptake on 18F-Fluoro-2-Deoxy-d-glucose Positron Emission Tomography/Computed Tomography Scan in a Patient with Acute Lymphoblastic Leukemia: A Typical Superscan Pattern Resembling NaF Positron Emission Tomography Scan.

Abbas Yousefi-Koma1, Yaser Shiravand2, Mohsen Qutbi2.   

Abstract

A 65-year-old patient with acute lymphoblastic leukemia presented for an 18fluoro-2-deoxy-d-glucose positron emission tomography computed tomography (18FDG PET) after several courses of chemotherapy for metastatic evaluation. Unexpectedly, on 18FDG PET scan, no discernible uptake was observed in the visceral organs, but instead, the skeleton/bone marrow showed homogenously intense metabolic activity. The distribution of 18FDG observed on the scan was remarkably similar to that on the NaF PET scan, indicating a superscan appearance. Copyright:
© 2019 Indian Journal of Nuclear Medicine.

Entities:  

Keywords:  18 fluoro-2-deoxy-d-glucose positron emission tomography computed tomography; acute lymphoblastic leukemia; bone marrow; diffuse uptake; skeleton; superscan

Year:  2019        PMID: 31579207      PMCID: PMC6771204          DOI: 10.4103/ijnm.IJNM_106_19

Source DB:  PubMed          Journal:  Indian J Nucl Med        ISSN: 0974-0244


A 65-year-old man with a history of acute lymphoblastic leukemia (L3 subtype) was referred for an 18F fluoro-2-deoxy-d-glucose positron emission tomography computed tomography (18 FDG PET/CT) for possible metastatic assessment. After obtaining an informed consent, an 18 FDG PET/CT scan was performed. The diagnosis was established by a bone marrow biopsy following a pancytopenia developed 2 years ago, and then, the chemotherapy was instituted shortly thereafter. After completion of 8 cycles of chemotherapy, the bone marrow biopsy examination revealed no leukemic involvement, but mild erythroid hyperplasia. Subsequently, a CT scan of the thorax was performed, on which, a few small nodules were detected in the lungs. Two months later, the patient underwent an 18 FDG PET/CT [Figure 1a], on which, a massive redistribution of the tracer from internal organs to the skeleton/bone marrow was noticed. Except mild physiological uptake in the brain, the visceral organs and soft tissue background activity were barely discernible. The most conspicuous finding on the maximum intensity projection image was the intense, homogeneous uptake in the axial and appendicular skeleton, suggesting diffuse bone marrow involvement. In addition, uptake irregularity of the renal parenchyma suspicious for tumoral involvement was evident. In Figure 1b, on enhancement of the brightness of the image in part “a” of Figure 1, the liver and spleen demonstrated faint uptake, and the background activity is still suppressed. As can be seen in Figure 2, the CT, PET, and fused PET/CT images from thorax (a), upper abdomen (b), and pelvis (c) demonstrate intense hypermetabolic pulmonary nodules in the right lung and substantial uptake in the bones as compared to faint uptake in the parenchyma of the liver and spleen. Two months later, despite the initiation of a new regimen of chemotherapy, the patient expired. “Superscan” appearance is an interesting terminology that has long been in use in nuclear medicine.[12] Initially, by definition, this terminology applied to a pattern on bone scintigraphy that assumes a condition in which the99 mTc-mthylene-diphosphonate is perfectly taken up in the skeletal system, and no background activity is noticed. Owing to the homogeneous distribution, this appearance resembles a normal scan but with much higher quality and is associated with varieties of metabolic disorders and rarely, widespread metastatic involvement of the skeleton.[123] Later, the application of this term is generalized to similar features in other scans or any dominant uptake limited to a specific organ, for example, liver,[45] suppressing uptake elsewhere, although some misuses have been occurred. Diffuse 18 FDG uptake in the skeleton and bone marrow as superscan pattern on PET scan has been reported in multiple malignant disorders, including lymphoma and leukemia,[67] multiple myeloma,[8] and metastasis like prostate cancer[910] as well as other hematologic conditions, for example, following administration of granulocyte colony-stimulating factor.[11] This finding is also observed in metabolic disorders such as renal osteodystrophy[12] and parathyroid carcinoma.[13] In this case, although some uptake in the brain and excretion via the urinary system are present, the uptake in the skeleton is sufficiently high and homogeneous that conforms, to a large extent, to the definition of superscan and bears a striking resemblance to an NaF PET scan, an exceptionally rare finding. In such conditions, because of less tracer available to accumulate in other organs, the detection of lesions may be compromised and more importantly, as in our patient, the prognosis is considerably poorer in patients without such finding.
Figure 1

Maximum intensity projections of 18FDG PET scan without (a) and with (b) brightness enhancement

Figure 2

CT (left), PET (middle) and fused PET/CT (right) slices of 18FDG PET scan from thorax (a), upper abdomen (b) and pelvis (c)

Maximum intensity projections of 18FDG PET scan without (a) and with (b) brightness enhancement CT (left), PET (middle) and fused PET/CT (right) slices of 18FDG PET scan from thorax (a), upper abdomen (b) and pelvis (c)

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  12 in total

1.  Significance of absent or faint kidney sign on bone scan.

Authors:  W M Sy; D Patel; H Faunce
Journal:  J Nucl Med       Date:  1975-06       Impact factor: 10.057

2.  Skeletal Superscan on 18F-FDG PET/CT in a Patient With Multiple Myeloma.

Authors:  Zhanli Fu; Xueqi Chen; Xing Yang; Qian Li
Journal:  Clin Nucl Med       Date:  2019-02       Impact factor: 7.794

3.  F-18 FDG PET superscan.

Authors:  Hung-Yi Su; Ren-Shyan Liu; Su-Quinn Liao; Shih-Jen Wang
Journal:  Clin Nucl Med       Date:  2006-01       Impact factor: 7.794

4.  FDG hepatic superscan caused by massive breast cancer invasion.

Authors:  Vladimir Tichelaar; Filip Gemmel; Willem de Rhoter; Carolien Bronkhorst; Hiltje de Graaf
Journal:  Clin Nucl Med       Date:  2009-10       Impact factor: 7.794

5.  18F-FDG PET/CT superscan in prostate cancer.

Authors:  Matthieu Bailly; Hélène Besse; Rémi Kerdraon; Gilles Metrard; Sabine Gauvain
Journal:  Clin Nucl Med       Date:  2014-10       Impact factor: 7.794

6.  Accuracy of 99mTC-diphosphonate bone scans and roentgenograms in the detection of prostate, breast and lung carcinoma metastases.

Authors:  J D Osmond; H P Pendergrass; M S Potsaid
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1975-12

7.  Diffuse bone marrow involvement of Hodgkin lymphoma mimics hematopoietic cytokine-mediated FDG uptake on FDG PET imaging.

Authors:  Stephen B Chiang; Alan Rebenstock; Liang Guan; Abass Alavi; Hongming Zhuang
Journal:  Clin Nucl Med       Date:  2003-08       Impact factor: 7.794

8.  18F-FDG hepatic superscan in a patient with chronic myeloid leukemia.

Authors:  Bulin Du; Xuena Li; Na Li; Yaming Li; Bailing Hsu
Journal:  Clin Nucl Med       Date:  2014-09       Impact factor: 7.794

9.  Superscan caused by renal osteodystrophy: Observed on 18F FDG PET/CT scan.

Authors:  Nasrin Ghesani; Jin Jung; Shyam Patel; Tekchand Ramchand
Journal:  Indian J Nucl Med       Date:  2013-10

10.  Super Scan Caused by Parathyroid Carcinoma Observed Both in18F-FDG PET/CT Scan and Tc-99m MDP Bone Scintigraphy.

Authors:  İsa Burak Güney; Semra Paydaş; Hüseyin Tuğsan Ballı
Journal:  Mol Imaging Radionucl Ther       Date:  2017-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.